Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Finance & Markets

KOSPI surges 5.9% as chipmakers rally on shareholder returns

The KOSPI surged past 6,800 on Thursday, as SK hynix and Samsung Electronics rallied on expectations for increased shareholder returns and easing U.S. Treasury yields boosted risk appetite. The benchmark KOSPI closed at 6,852.58, up 5.89 percent from the previous session. The index opened 3.23 percent higher and extended its advance, triggering a buying-side sidecar at 9:57 a.m. It was the 49th…

KOSPI surges 5.9% as chipmakers rally on shareholder returns

The KOSPI index experienced a significant surge of 5.9% on Thursday, reaching a closing value of 6,852.58, driven by strong performances from chipmakers SK hynix and Samsung Electronics. This rally was fueled by investor expectations of increased shareholder returns and a positive impact from easing U.S. Treasury yields, which boosted risk appetite.

The index opened 3.23% higher and activated a buying-side sidecar at 9:57 a.m., marking the 49th sidecar activation of the year. Foreign investors contributed to the positive momentum by purchasing a net 1.7 trillion won worth of shares, while institutional and retail investors sold shares in the amount of 219.5 billion won and 2.3 trillion won, respectively.

The surge in SK hynix and Samsung Electronics was particularly notable, with SK hynix surging 12.73% to close at 1,691,000 won following its announcement of a 40 trillion won share buyback and cancellation program. This move aimed to counteract profit-taking pressure following its recent rally, and the company also reinforced its shareholder return policy.

Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Read the original at koreatimes.co.kr →

More in Finance & Markets

Telix half year revenue increases 22 per cent to 477 million dollars

Radiopharmaceutical manufacturer Telix Pharmaceuticals reported 477 million dollars in half year group revenue on 20 August 2026 boosting gross margin to 55 per cent

  • Telix Pharmaceuticals revenue grew 22% to US$477 million in H1 2026
  • Gross margin improved by 2% to 55%, Precision Medicine margin up 1% to 65%
  • Company invested US$124 million in R&D for late-stage programs and Regeneron collaboration

More from Thursday 20 August →